Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis

E. Randall Lanier, Scott Foster, Tom Brundage, Sunwen Chou, Mark N. Prichard, Steven Kleiboeker, Chad Wilson, Donella Colville, Herve Mommeja-Marin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Brincidofovir is an oral antiviral in development for prevention of cytomegalovirus disease. Cytomegalovirus genotyping results from a phase 2 trial comparing brincidofovir to placebo for prophylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initial data on the clinical resistance profile for brincidofovir. In this study, no known resistance-associated mutations were detected in brincidofovir-treated subjects; identified genotypic substitutions did not confer resistance to cytomegalovirus antivirals in vitro, suggesting that these changes represent polymorphisms unrelated to brincidofovir resistance. Lack of evidence for genotypic resistance during prophylaxis suggests that first-line use of brincidofovir for prevention of cytomegalovirus infection may preserve downstream options for patients.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalJournal of Infectious Diseases
Volume214
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

DNA-Directed DNA Polymerase
Cytomegalovirus
Clinical Trials
Mutation
Genes
Cytomegalovirus Infections
Antiviral Agents
cidofovir hexadecyloxypropyl ester
Placebos
Transplants

Keywords

  • Brincidofovir
  • CMV
  • CMV (DNA) polymerase
  • CMV phosphotransferase
  • cytomegalovirus
  • stem cell transplantation
  • UL54
  • UL97

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. / Randall Lanier, E.; Foster, Scott; Brundage, Tom; Chou, Sunwen; Prichard, Mark N.; Kleiboeker, Steven; Wilson, Chad; Colville, Donella; Mommeja-Marin, Herve.

In: Journal of Infectious Diseases, Vol. 214, No. 1, 01.07.2016, p. 32-35.

Research output: Contribution to journalArticle

Randall Lanier, E, Foster, S, Brundage, T, Chou, S, Prichard, MN, Kleiboeker, S, Wilson, C, Colville, D & Mommeja-Marin, H 2016, 'Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis', Journal of Infectious Diseases, vol. 214, no. 1, pp. 32-35. https://doi.org/10.1093/infdis/jiw073
Randall Lanier, E. ; Foster, Scott ; Brundage, Tom ; Chou, Sunwen ; Prichard, Mark N. ; Kleiboeker, Steven ; Wilson, Chad ; Colville, Donella ; Mommeja-Marin, Herve. / Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. In: Journal of Infectious Diseases. 2016 ; Vol. 214, No. 1. pp. 32-35.
@article{fa6735f507084156ab78aebfe000bffa,
title = "Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis",
abstract = "Brincidofovir is an oral antiviral in development for prevention of cytomegalovirus disease. Cytomegalovirus genotyping results from a phase 2 trial comparing brincidofovir to placebo for prophylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initial data on the clinical resistance profile for brincidofovir. In this study, no known resistance-associated mutations were detected in brincidofovir-treated subjects; identified genotypic substitutions did not confer resistance to cytomegalovirus antivirals in vitro, suggesting that these changes represent polymorphisms unrelated to brincidofovir resistance. Lack of evidence for genotypic resistance during prophylaxis suggests that first-line use of brincidofovir for prevention of cytomegalovirus infection may preserve downstream options for patients.",
keywords = "Brincidofovir, CMV, CMV (DNA) polymerase, CMV phosphotransferase, cytomegalovirus, stem cell transplantation, UL54, UL97",
author = "{Randall Lanier}, E. and Scott Foster and Tom Brundage and Sunwen Chou and Prichard, {Mark N.} and Steven Kleiboeker and Chad Wilson and Donella Colville and Herve Mommeja-Marin",
year = "2016",
month = "7",
day = "1",
doi = "10.1093/infdis/jiw073",
language = "English (US)",
volume = "214",
pages = "32--35",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis

AU - Randall Lanier, E.

AU - Foster, Scott

AU - Brundage, Tom

AU - Chou, Sunwen

AU - Prichard, Mark N.

AU - Kleiboeker, Steven

AU - Wilson, Chad

AU - Colville, Donella

AU - Mommeja-Marin, Herve

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Brincidofovir is an oral antiviral in development for prevention of cytomegalovirus disease. Cytomegalovirus genotyping results from a phase 2 trial comparing brincidofovir to placebo for prophylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initial data on the clinical resistance profile for brincidofovir. In this study, no known resistance-associated mutations were detected in brincidofovir-treated subjects; identified genotypic substitutions did not confer resistance to cytomegalovirus antivirals in vitro, suggesting that these changes represent polymorphisms unrelated to brincidofovir resistance. Lack of evidence for genotypic resistance during prophylaxis suggests that first-line use of brincidofovir for prevention of cytomegalovirus infection may preserve downstream options for patients.

AB - Brincidofovir is an oral antiviral in development for prevention of cytomegalovirus disease. Cytomegalovirus genotyping results from a phase 2 trial comparing brincidofovir to placebo for prophylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initial data on the clinical resistance profile for brincidofovir. In this study, no known resistance-associated mutations were detected in brincidofovir-treated subjects; identified genotypic substitutions did not confer resistance to cytomegalovirus antivirals in vitro, suggesting that these changes represent polymorphisms unrelated to brincidofovir resistance. Lack of evidence for genotypic resistance during prophylaxis suggests that first-line use of brincidofovir for prevention of cytomegalovirus infection may preserve downstream options for patients.

KW - Brincidofovir

KW - CMV

KW - CMV (DNA) polymerase

KW - CMV phosphotransferase

KW - cytomegalovirus

KW - stem cell transplantation

KW - UL54

KW - UL97

UR - http://www.scopus.com/inward/record.url?scp=84979266779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979266779&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiw073

DO - 10.1093/infdis/jiw073

M3 - Article

VL - 214

SP - 32

EP - 35

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -